<DOC>
	<DOCNO>NCT00027417</DOCNO>
	<brief_summary>This study determine safety efficacy liothyronine sodium/triiodothyronine ( Triostat ) , synthetic thyroid hormone , give infant congenital heart disease cardiopulmonary bypass surgery .</brief_summary>
	<brief_title>Study Triostat Infants During Heart Surgery</brief_title>
	<detailed_description>Patients randomize receive study drug placebo randomization occur stratify diagnostic category . All patient undergo preoperative echocardiogram provide preoperative cardiac function data . The study drug placebo provide operating room iv bolus prior cardiopulmonary bypass bolus deliver release aortic cross-clamp . This follow iv 12 hour . Operative data collect include CPB time , aortic cross-clamp time , length degree hypothermia . These data extract anesthesia record .</detailed_description>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<criteria>Inclusion criterion : Diagnosis one following : Ventricular septal defect ( VSD ) Infant coarctation aorta Transposition great artery Tetralogy Fallot Complete atrioventricular canal defect Hypoplastic leave heart , include patient undergo Norwood type procedure aortic mitral atresia Patient must schedule surgery . Exclusion criterion : Certain additional defect and/or requirement additional surgery .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Congenital heart defect</keyword>
	<keyword>Hypoplastic leave heart syndrome</keyword>
	<keyword>Complete atrioventricular canal defect</keyword>
	<keyword>Triostat</keyword>
	<keyword>Cardiac surgery</keyword>
</DOC>